Loading...
Market
Ionis Pharmaceuticals stock price increases by 20% or more by Aug 31?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
NASDAQ stock price data
Story
Ionis Reports Positive Results for Donidalorsen in OASIS-HAE and OASISplus Trials
May 31, 2024, 03:02 PM
Ionis Pharmaceuticals has announced positive results from two late-stage trials, OASIS-HAE and OASISplus, for its investigational therapy donidalorsen in treating hereditary angioedema (HAE). The trials demonstrated that donidalorsen, which targets prekallikrein mRNA, significantly reduced the attack rate in patients compared to a placebo. These benefits were observed even in patients currently on other HAE medications. $IONS (-1.0% pre).
View original story
Similar markets
Increase by more than 20% • 33%
Increase by 0-20% • 33%
Decrease • 33%
Stock price increase • 50%
Stock price decrease • 50%
Increase by over 20% • 33%
Increase by 10-20% • 33%
Increase by less than 10% • 34%
